Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms Zoster-048
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 27 Feb 2020 Results from post-hoc analyses on the correlation between humoral and CMI responses and polyfunctional CD4 T-cell responses published in the Journal of Infectious Diseases
  • 07 Oct 2018 Results presented at the IDWeek 2018
  • 08 Oct 2017 Primary endpoint (Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations-non-inferiority) has been met, according to results presented at the IDWeek 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top